Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10916136 | Nuclear Medicine and Biology | 2012 | 5 Pages |
Abstract
These results demonstrate the bivalent character of laniquidar, acting as a substrate at low doses and as a blocking agent for P-glycoprotein transport in the brain at higher doses. In comparison, no difference was observed in [11C]-dLop uptake between carrier- and no-carrier-added formulations, which confirms that desmethyl-loperamide is a substrate of P-glycoprotein at the blood-brain barrier.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Lieselotte Moerman, Caroline Dumolyn, Paul Boon, Filip De Vos,